Navigation Links
Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
Date:8/6/2012

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. The Phase II, open-label, multicenter study in patients with advanced neuroendocrine tumors (NET) whose symptoms were no longer responsive to octreotide LAR therapy found that the drug was effective and well tolerated in controlling patient symptoms.

The study results are reported in a recent issue of Endocrine-Related Cancer, a publication of the Society for Endocrinology.

"Neuroendocrine tumors are often asymptomatic and, by the time of diagnosis, have frequently metastasized, usually to the liver," said the study's corresponding author, Larry K. Kvols, M.D., a senior member at Moffitt and section head of neuroendocrine oncology. "Surgery is essential in managing metastatic NET and can be curative for early disease, but the majority of patients need further treatment."

According to Kvols, octreotide and lanreotide, drugs that mimic natural somatostatin, have been "the mainstay" for symptom management of neuroendocrine tumors. However, many patients eventually fail to respond to this treatment and have poor prognoses.

"Pasireotide is a novel multireceptor-targeted somatostatin analogue that binds to four of the five known somatostatin receptor subtypes," said Kvols, whose research is in experimental therapies for neuroendocrine cancer. "Because of its binding ability, it may offer symptom reduction for patients who have eventually failed to respond to traditional therapy."

The multicenter clinical trial, conducted at sites in the United States and Europe, enrolled 89 patients and evaluated 44 for efficacy and 45 for tolerability. Pasireotide "effectively controlled symptoms." Evaluation of tumor response in 23 patients showed 13 with stable disease and 10 with progressive disease. The drug was "effective and well-tolerated" and adverse events, most commonly gastrointestinal, were "mild or moderately severe."

The study was funded in part through funding by Novaratis Pharmaceuticals.

A Phase III study evaluating pasireotide versus octreotide is ongoing for patients with advanced NET whose disease-related symptoms have been inadequately controlled.


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce and ... U.S. universities who will draw from Siemens’ deep knowledge of product development ...
(Date:2/12/2016)... , ... February 12, 2016 , ... As a former ... schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn to ... to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice with ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Every winter, ... , This winter the West Penn Burn Center, part of the Allegheny ... #1, to bring you the “Space Heaters Need Space” campaign. , ...
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a ... OH area. The latest campaign focuses on the fight against breast cancer, fundraising for ... being accepted here . , Carmen is a loving single mother of two ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & ... continuing it’s commitment to act as Agents of Change in the community, announces ... area homeless families to fulfill immediate needs and help them move into permanent ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... the Company will ring the Nasdaq Closing Bell at ... York at 4:00 p.m. ET on Tuesday, ... Adrian Adams , will perform the ... to 4:00 p.m. ET.  A live webcast will be ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
Breaking Medicine Technology: